December 16, 2016 08:37 AM EST

CRISPR/Cas9 players create an IP alliance as the war with Editas heats up

John Carroll

Editor & Founder

Some of the most prominent players in the gene editing field have created an IP-sharing alliance on their CRISPR-Cas9 tech, and Editas $EDIT is conspicuously …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR/Cas9 players create an IP alliance as the war with Editas heats up

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

A look at biotech's year of the megaround

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials

CRISPR/Cas9 play­ers cre­ate an IP al­liance as the war with Ed­i­tas heats up

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

CRISPR/Cas9 players create an IP alliance as the war with Editas heats up

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials